Ascendis Pharma A/S (NASDAQ:ASND) Now Covered by Analysts at Barclays

Stock analysts at Barclays assumed coverage on shares of Ascendis Pharma A/S (NASDAQ:ASND) in a research note issued on Tuesday, Marketbeat reports. The firm set an “overweight” rating and a $342.00 price target on the biotechnology company’s stock. Barclays‘s target price suggests a potential upside of 53.74% from the company’s previous close.

Several other equities analysts have also issued reports on ASND. Weiss Ratings reissued a “sell (d-)” rating on shares of Ascendis Pharma A/S in a report on Wednesday, January 21st. Raymond James Financial started coverage on Ascendis Pharma A/S in a report on Friday, October 17th. They set a “strong-buy” rating and a $271.00 target price on the stock. Wedbush reissued an “outperform” rating and issued a $220.00 target price on shares of Ascendis Pharma A/S in a research note on Tuesday, November 18th. Stifel Nicolaus raised their price target on Ascendis Pharma A/S from $254.00 to $256.00 and gave the stock a “buy” rating in a research report on Thursday, December 11th. Finally, Royal Bank Of Canada boosted their price objective on Ascendis Pharma A/S from $245.00 to $250.00 and gave the company an “outperform” rating in a research report on Tuesday, January 20th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Ascendis Pharma A/S has an average rating of “Buy” and a consensus price target of $269.00.

Ascendis Pharma A/S Trading Down 6.8%

Ascendis Pharma A/S stock opened at $222.45 on Tuesday. The firm has a market capitalization of $13.79 billion, a P/E ratio of -50.10, a PEG ratio of 1.26 and a beta of 0.46. The business has a 50-day moving average of $211.58 and a 200-day moving average of $200.80. Ascendis Pharma A/S has a 1 year low of $118.03 and a 1 year high of $242.00.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings results on Thursday, November 13th. The biotechnology company reported ($1.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.76). The company had revenue of $250.71 million for the quarter, compared to analyst estimates of $246.91 million. Research analysts anticipate that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Institutional Investors Weigh In On Ascendis Pharma A/S

Several institutional investors have recently bought and sold shares of ASND. Calamos Advisors LLC boosted its position in Ascendis Pharma A/S by 152.7% during the 4th quarter. Calamos Advisors LLC now owns 16,300 shares of the biotechnology company’s stock worth $3,476,000 after acquiring an additional 9,850 shares during the last quarter. Chicago Partners Investment Group LLC lifted its position in shares of Ascendis Pharma A/S by 14.2% in the fourth quarter. Chicago Partners Investment Group LLC now owns 3,498 shares of the biotechnology company’s stock worth $823,000 after purchasing an additional 436 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Ascendis Pharma A/S by 14.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,941 shares of the biotechnology company’s stock worth $1,480,000 after purchasing an additional 860 shares during the last quarter. CWM LLC grew its position in Ascendis Pharma A/S by 34,775.0% in the fourth quarter. CWM LLC now owns 1,395 shares of the biotechnology company’s stock valued at $297,000 after purchasing an additional 1,391 shares in the last quarter. Finally, Farther Finance Advisors LLC increased its stake in Ascendis Pharma A/S by 15.1% in the 4th quarter. Farther Finance Advisors LLC now owns 550 shares of the biotechnology company’s stock valued at $117,000 after buying an additional 72 shares during the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.